HIKAL Intraday Analysis...

HIKAL Share Price

Open 213.95 Change Price %
High 214.00 1 Day 0.70 0.33
Low 211.65 1 Week 2.15 1.02
Close 212.65 1 Month 19.10 9.87
Volume 37255 1 Year 69.35 48.39
52 Week High 256.80
52 Week Low 138.70
HIKAL Important Levels
Resistance 2 214.83
Resistance 1 213.93
Pivot 212.77
Support 1 211.37
Support 2 210.47
NSE INDIA Most Active Stocks
SUZLON 20.85 0.24%
GMRINFRA 17.15 -3.92%
JPASSOCIAT 13.10 0.77%
ADANIENT 118.55 -20.94%
IBREALEST 154.05 -2.59%
IDFCBANK 61.20 3.03%
SOUTHBANK 24.15 -3.21%
PNB 167.15 3.76%
UNITECH 5.70 -2.56%
JPINFRATEC 13.85 6.95%
NSE INDIA Top Gainers Stocks
KSERASERA 0.20 33.33%
VSSL 124.80 20.00%
ATNINTER 0.30 20.00%
RKDL 13.65 19.74%
WELINV 127.75 18.29%
TCIDEVELOP 533.00 17.56%
HBSTOCK 25.65 16.06%
HUBTOWN 146.30 12.50%
SYNCOM 6.75 12.50%
NAKODA 0.45 12.50%
NSE INDIA Top Losers Stocks
BLS 170.40 -89.85%
ADANIENT 118.55 -20.94%
SHILPI 165.90 -19.99%
AUSTRAL 0.25 -16.67%
MAHASTEEL 85.25 -9.74%
ZENSARTECH 838.65 -8.73%
KAMATHOTEL 45.05 -8.53%
ZENITHBIR 0.55 -8.33%
NICCO 0.55 -8.33%
ROLLT 9.75 -8.02%

Hikal Limited (NSE: HIKAL)

HIKAL Technical Analysis 3
As on 26th Apr 2017 HIKAL Share Price closed @ 212.65 and we RECOMMEND Buy for LONG-TERM with Stoploss of 198.59 & Buy for SHORT-TERM with Stoploss of 210.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
HIKAL Target for April
1st Target up-side 228.74
2nd Target up-side 239.24
3rd Target up-side 249.75
1st Target down-side 198.76
2nd Target down-side 188.26
3rd Target down-side 177.75
HIKAL Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 51.88 Sideways
MFI (14) MFI is 60.00 Sideways
CCI (20) CCI is -18.08 Sideways
WILLIAM %R (14) William %R is -64.29 Sideways
ADX (14) ADX is 13.92 Range Bound
PSAR Stoploss For Short Sell 224.20
10 Day Avg Volume Traded -51.52 % Less then 10 Day Average Volume
HIKAL Other Details
Segment EQ
Market Capital 0.00
Sector Basic Materials
Industry Chemicals - Major Diversified
Offical website http://www.hikal.com
HIKAL Address
717/718, Maker Chambers V
Nariman Point
Mumbai, 400021
HIKAL Latest News
Hikal Ltd opts for stock split   Hindu Business Line   - 17th Dec 14
Hikal board to decide on stock-split   Hindu Business Line   - 16th Dec 14
ICRA upgrades Credit Rating of Hikal Ltd   Equity Bulls   - 08th Aug 14
Upgradation in the Credit Rating   Hindu Business Line   - 07th Aug 14
Hikal gets FDA nod for Gujarat facility   Hindu Business Line   - 26th Apr 13
Hikal To Raise Debt From IFC   DealCurry   - 02nd Mar 13
Limited downside seen in Hikal, says Rajen Shah   Moneycontrol.com   - 18th May 12
Angel Broking bets on multibaggers Hikal and Finolex Cables   Moneycontrol.com   - 29th Dec 11
Hikal Limited   Moneycontrol.com   - 07th Dec 10
Hikal commissions new agro-chemical plant at Taloja   Economic Times   - 30th Jun 08
Interactive Technical Analysis Chart Hikal Limited ( HIKAL NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Hikal Limited
HIKAL Business Profile
Hikal (HIKAL), is in the business of providing a broad spectrum of R&D and custom manufacturing solutions to the pharmaceuticals, biotech, agrochemicals and specialty chemicals industries. The Company was incorporated on July 8, 1988. The company provides active ingredients, intermediates and R&D services and solutions. It supplies molecules for discovery research on a contract basis, develops non-infringing processes and scales them up to commercial scale production, undertakes method validation of new substances and custom manufacturing of key intermediates and active substances for pharmaceutical and agrochemical companies worldwide. The pharmaceutical intermediates are manufactured at Panoli, Gujarat and active ingredients are manufactured in Bangalore meeting regulated markets (US, Europe and Japan) standards. Commercialized APIs developed include Gabapentin, Ondansetron Hydrochloride, and Valproic acid; intermediates include Gabapentin Lactam, benzylchloride, among others. The company specializes in custom synthesis and contract manufacture of agrochemicals, intermediates and specialty chemicals by developing non-infringing processes for molecules and analytical development. Its Taloja, Panoli, and Mahad plants are ISO 17025, ISO 9000-2000, ISO 14001 and OHSAS18001 certified. Active ingredients include diuron and quinalphos; intermediates and specialty chemicals include 4-methyl thiazole, meta chloro aniline, among others. It also provides formulations including emulsifiable concentrates, wettable powders, suspension concentrates, and water dispersible granules. The company has long term agreements to supply the German company Degussa AG with pharmaceutical intermediates and active pharma ingredients (APIs) and the US-based Alpharma with active pharmaceutical ingredient (API) for the veterinary sector. The company operates mainly in India, United States, Canada, Europe, Africa South America, and South East Asia. It has investments in Jiangsu Chemstar Industries Co. and a shareholding of 16% in Chemstar Industries. The current market capitalization stands at Rs 780.90 crore. The company has reported a standalone sales of Rs 202.79 crore and a Net Profit of Rs 14.12 crore for the quarter ended September 2013. The company management includes Jai Hiremath - Chairman & Managing Director, Sameer Hiremath - Joint Managing Director, Baba Kalyani - Director, Prakash Mehta - Director, Shivkumar Kheny - Director, Kannan Unni - Director, Peter Pollak - Director, Amit Kalyani - Director, Wolfgang Welter - Director, Sugandha Hiremath - Director. The Registered office is at 717/718, Maker Chambers V, Nariman Point Mumbai, Maharashtra - 400021.